News

Recombinant human Interleukin-7 (r-hIL-7) is a critical growth factor for immune T-cell recovery and enhancement. Laureate claims that clinical investigations conducted on more than 75 patients in Europe,

Each unit will be comprised of one common share of the company and one half of one share purchase warrant. Each whole warrant will entitle the holder to

The company said that the technology can be used for site-specific delivery of several drugs in a time-release fashion from combination medical devices. The patent reportedly augments and

As announced in October 2007, the FDA in the US has requested additional clinical data prior to submission of a new drug application (NDA) for TAK-475 and recommended

In a controlled clinical trial with 59 gastroesofageal reflux disease (GERD) patients treated for 14 days, the anti-secretory effect of OX17 was compared to omeprazole and famotidine. The

The laboratory will focus on the biosynthesis pathway inhibition of the major components of the fungal cell membranes to further develop the company’s intellectual properties. Another key function

The new data also showed that degarelix provided an extremely fast effect on testosterone levels, close to the immediate effect achieved with surgery (orchidectomy), the company said. The

The licensed technologies, which were co-developed by FluoroPharma and Massachusetts General Hospital (MGH) scientists, target multiple biological processes associated with Alzheimer’s disease. According to the available sources, currently,

The Sedasys System is intended for use by physician/nurse teams to administer minimal to moderate propofol sedation to patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy),